Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1792505 | 0.81 | IGF1R (0.62) | IGF1RSLC5A7 | |
| SCHEMBL4463976 | 0.77 | IGF1R (0.45) | IGF1RSLC5A7 | |
| SCHEMBL1792954 | 0.77 | IGF1R (0.47) | IGF1RSLC5A7 | |
| SCHEMBL1792577 | 0.73 | IGF1R (0.46) | IGF1RSLC5A7 | |
| SCHEMBL4463994 | 0.64 | IGF1R (0.31) | IGF1R | |
| SCHEMBL1795880 | 0.63 | IGF1R (0.66) | IGF1R | |
| SCHEMBL1788923 | 0.62 | IGF1R (0.47) | IGF1RSLC5A7 | |
| SCHEMBL11346470 | 0.61 | IGF1R (1.00) | IGF1R | |
| SCHEMBL4457078 | 0.59 | IGF1R (0.41) | IGF1R | |
| SCHEMBL1790427 | 0.59 | ALDH1A1 (0.36) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | IGF1R 2279/4885SLC5A7 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.